The drug "Reaferon" (suppositories, powder) has an immunomodulating, antitumor and antiviral effect. The powder is intended for the preparation of a solution for administration to the muscle and topical application. The drug "Reaferon" (interferon alfa-2a) has pyrogenic activity.
The medicine is prescribed in complex therapy for adults with hepatitis B (acute viral) in severe and moderate forms at the beginning of the icteric stage until the fifth day of jaundice, viral conjunctivitis, keratitis, keratoconjunctivitis, keratouveitis. The drug "Reaferon" instruction recommends for multiple sclerosis, hairy cell leukemia, kidney cancer of the fourth degree.
The medication is contraindicated in allergic pathologies (including polyvalent allergies), pregnancy, hypersensitivity. Means "Reaferon" instruction does not allow for the appointment of patients in childhood.
Among the undesirable manifestations with the introduction of the drug, itching, rashes on the skin, fever, fatigue, chills, thrombocytopenia, leukopenia should be noted. The indicated adverse reactions to the Reaferon medication are not considered by the instructions as the reason for discontinuing treatment.
With local use of the drug, the development of edema, irritation or conjunctival infection is possible. The drug can cause the occurrence of single follicles.
The medicine "Reaferon" instruction recommends to be administered subconjunctival, intramuscularly or used topically.
For an injection into the muscle, the contents of the ampoule must be dissolved in a milliliter of 0.9% NaCl solution.
With hepatitis B (acute), one million IU is used twice a day. This dose is administered for five to six days. After the dosage is reduced to one million IU once a day and is applied for another five days. After monitoring biochemical parameters in the blood, therapy is continued if necessary. The dosage of the Reaferon preparation at the same time recommends setting one million IU twice a week for two weeks. The amount of the drug per therapeutic course is 15-20 million IU.
For kidney cancer, Reaferon recommends a dose of three million IU daily for use. The duration of treatment is ten days. If necessary, repeated therapy (from three to nine or more courses) is carried out at intervals of three weeks. The total dosage per course is from ninety to two hundred and seventy million IU or more.
For hairy cell leukemia, the Reaferon drug is administered in an amount of three to six million IU (in accordance with individual tolerance) for two months. Maintenance therapy is prescribed after normalization of the hemogram. In this case, a dosage of three million IU is recommended twice a week for an extended period. The total dose per course is 420-600 million IU or more.
In sclerosis (multiple), one million IU is prescribed three times a day for pyramidal syndrome, once or twice a day for cerebellar syndrome. Treatment is carried out for ten days. After a ten-day course, 1 million IU are transferred to the management once a week for five or six months. The total dose per course is from fifty to sixty million IU.
Subconjunctival administration is carried out with keratidocyclitis and stromal keratitis in a dose of sixty thousand IU every other day or every day in accordance with the severity of the process. Injections are carried out under local anesthesia with a solution of tetracaine 0.5%. The duration of therapy is fifteen to twenty-five injections.
Locally, the drug is instilled in two drops six to eight times a day with superficial keratitis and conjunctivitis. Instillations are carried out in the affected eye. As the condition alleviates, the number of administrations is reduced to three to four per day. The duration of therapy is two weeks.
Before using Reaferon medication, it is necessary to carefully study the annotation and consult a doctor.